Eagle Radio

Eagle Radio


Visit Absolute Aesthetics website to find out more
Visit Absolute Aesthetics website to find out more

Drug trialled in Surrey could extend cancer patients lives

3 minute read
Drug trialled in Surrey could extend cancer patients lives

Published at 6:29am 11th July 2017.

A new drug has been introduced to control the symptoms of kidney cancer - and extend patients' lives. 

The tablet has been given the go ahead by NICE following a University of Surrey study.

Renal cell cancer is the most common type of kidney cancer, accounting for 80-90% of kidney cancers in the UK. 

Around 11,900 new cases are diagnosed every year in the UK - 33 a day. Kidney cancer is the seventh most common cancer in the UK.

Patients taking this new medication could live for up to tem years longer - rather than 6-9 months.

It is a new therapy option to help battle cancer resistance in advanced renal cell carcinoma in adults.

Cabozantinib is a once-daily oral tablet which targets multiple pathways involved in tumour growth.

It has been approved by NICE for routine access by English and Welsh patients.

The drug has been shown to significantly extend overall survival and progression free survival compared with everolimus, with over five times more patients responding to treatment.

Professor Panda, an Oncologist in Guildford who led the trials at the University of Surrey, said it's an important step forward: "What NICE have done is effectively allowed oncologists to access this drug on behalf of patients so we have some treatment choices.

"The one key difference with this drug compared with others is that it seems to be able to target factors in the cancer cells which appear because they are resistant to other treatments.

"In other words they wouldn't be there first time round - but they start to appear on the cancer cell surface.

"And are targetable - we can fire bullets at them, because they appear a little bit later."

"The approval of cabozantinib is welcome news for clinicians and people with advanced kidney cancer in England and Wales.

Professor Robert Hawkins, Consultant Oncologist at Manchester's Christie NHS Foundation Trust said: "We have been fortunate enough to already see the benefits of this treatment in patients enrolled in the managed access scheme, and we are delighted that wider access means more people with kidney cancer will be able to live longer.

"There is a real need for new treatments among patients with advanced or relapsing kidney cancer and cabozantinib has demonstrated strong potential among these patients where there is an urgent need for new advances that extend and improve lives."


Contact Us

If you would like to submit a query or provide more information on this story please get in touch below.

Please wait...
  • Up to 3 JPG or PNG images, 2MB max size
  • We will always endeavour to credit you when we publish your pictures.
  • By uploading you are agreeing to this non-exclusive reuse, royalty-free, across all Eagle Radio platforms, which extends to our partner broadcasters.
  • You retain copyright to all images.
  • If you would like to send us a video, please upload to YouTube or similar and paste the video URL into the message above.